Table 1 Baseline study characteristics

Cooper et al./CRIT 2011 [4]

21

24

LTS: hematocrit < 30% with post-transfusion goal of 30–33%

RTS: hematocrit < 24% with post-transfusion goal 24–27%

AMI (ischemic-type chest discomfort lasting ≥ 30 min and associated with a creatine kinase-MB (CK-MB) or cardiac troponin level above the upper limit of normal. Hematocrit ≤ 30% within 72 h of symptom onset

Age < 21; non-coronary cause for clinical syndrome; active bleeding; RBC transfusion within 7 days of enrollment; imminent death; pregnancy

STE/NSTE

1 month

All-cause mortality; in-hospital mortality; recurrent MI/ACS, 30-day mortality

Carson et al. 2013 [5]

55

55

LTS: < 10 g/dl with post-transfusion goal > 10 g/dl

RTS: < 8 g/dl or symptomatic for post-transfusion goal > 8 g/dl

Age ≥ 18; STEMI, NSTEMI, unstable angina, stable CAD undergoing cardiac catheterization; Hb < 10 g/dl at the time of random allocation

Hgb > 10; symptoms of anemia at the time of randomization; cardiac surgery within 30 days; severe illness; Ventilated/intubated; hemodynamic instability

STE/NSTE/stable angina

1 month

All-cause mortality; in-hospital mortality; recurrent MI/ACS; 30-day mortality

Ducrocq et al. 2021/REALITY [6]

324

342

LTS: ≤ 10 g/dl, with post-transfusion goal ≥ 11 g/dl

RTS: ≤ 8 g/dl, with post-transfusion goal 8–10 g/dl

Age ≥ 18; AMI (with or without ST-segment elevation with a combination of ischemic symptoms occurring in the 48 h before admission and elevation of biomarkers, and Hb 7–10 g/dl

Shock; MI occurring after PCI or CABG; life-threatening or massive ongoing bleeding; blood transfusion in the past 30 days; malignant hematologic disease

STE/NSTE

1 month

All-cause mortality; in-hospital mortality; recurrent MI/ACS; 30-day mortality